ACTRAPID PENFILL 100IU 1ML

ACTRAPID PENFILL 100IU 1ML is a medication that contains insulin, a hormone produced by the pancreas. It is primarily used to manage high blood sugar levels in patients with diabetes. Insulin helps regulate glucose (sugar) in the blood by allowing it to enter cells, where it is used as an energy source. ACTRAPID PENFILL comes in a pre-filled pen device for convenient and accurate dosing. It is a short-acting insulin, which means it starts working quickly and has a shorter duration of action compared to long-acting insulins.

Side Effects:

While ACTRAPID PENFILL is generally well-tolerated, it may cause certain side effects. It is important to note that not all patients will experience these side effects, and their severity may vary. Common side effects of ACTRAPID PENFILL may include:

1. Hypoglycemia (low blood sugar): Symptoms may include shakiness, dizziness, sweating, confusion, headache, rapid heartbeat, or weakness. It is important to monitor blood sugar levels closely and take appropriate steps to manage and prevent hypoglycemia.
2. Injection site reactions: Redness, swelling, or itching at the injection site may occur. These reactions are usually mild and transient.
3. Weight gain: Insulin therapy can lead to weight gain in some individuals.
4. Hypokalemia (low potassium levels): Insulin can cause a decrease in potassium levels in the blood, which may lead to symptoms such as muscle weakness, cramps, or irregular heartbeat.

It is important to promptly report any persistent or severe side effects to a healthcare professional for further evaluation and guidance.

When Not to Use:

There are certain circumstances when the use of ACTRAPID PENFILL should be avoided. Here are some instances when it is contraindicated:

1. Hypersensitivity: If you have a known hypersensitivity or allergy to insulin or any of the ingredients present in ACTRAPID PENFILL, its use should be avoided.
2. Hypoglycemia Unawareness: ACTRAPID PENFILL should not be used in patients with a history of hypoglycemia unawareness. These individuals may be unable to recognize the early warning signs of low blood sugar levels, putting them at higher risk for severe hypoglycemic episodes.
3. Hypokalemia: Use caution when prescribing ACTRAPID PENFILL to patients with hypokalemia, as insulin can further lower potassium levels.
4. Diabetic Ketoacidosis (DKA): ACTRAPID PENFILL is not suitable for the treatment of diabetic ketoacidosis, a life-threatening condition characterized by high blood sugar, ketones in the urine, and metabolic acidosis. Prompt medical attention is required in such cases.

Note: This is a general description, and it is important to consult a healthcare professional or refer to the medication’s package insert for complete and accurate information about ACTRAPID PENFILL, including dosing instructions, precautions, and potential drug interactions.